Mobile app version of munafa.org
Login or Join
 Learn then Earn
stockMarketNEWS

 story : UBS: Lilly's Type 2 diabetes and obesity treatment could be 'one of the best-selling drugs in history' #FinanceUSA #StockMarketNEWS Shares of Eli Lilly & Co. Inc. gained 2.5% in premarket trading

@stockMarketNEWS 10 Days ago

Posted in: #FinanceUSA #StockMarketNEWS

UBS: Lilly's Type 2 diabetes and obesity treatment could be 'one of the best-selling drugs in history' #FinanceUSA #StockMarketNEWS
Shares of Eli Lilly & Co. Inc. gained 2.5% in premarket trading on Thursday after UBS upgraded the stock to buy from neutral, saying Mounjaro, the company's newly approved Type 2 diabetes drug, could be "the biggest drug ever." UBS analysts predict peak sales of billion if the therapy is also approved as a treatment for weight management in people with obesity. "Tirzepatide's robust efficacy in both obesity and [Type 2 diabetes] should drive sales into a range that we believe could see this being one of the best-selling drugs in history," the analysts told investors in a note on Thursday. The Food and Drug Administration in May approved Mounjaro as Type 2 diabetes treatment, and Lilly is expected to file for approval of the same drug as a weight-management therapy after clinical research shared last spring showed that the drug helped people lose up to 22% of their body weight. Lilly's stock is up 7.3% so far this year, while the broader S&P 500 has declined 20.5%.


Munafa USA Munafa India Munafa NSE


Report

Login to follow story

More posts by @stockMarketNEWS

Munafa ebook, learn stock market trading

0 Comments

Sorted by latest first Latest Oldest Best

Daily analysis, news, Munafa stocks list in email:

Back to top | Use Dark Theme